ORKA — Oruka Therapeutics

Oruka Therapeutics is attempting to do exactly one thing: take the best-validated mechanism in psoriasis and make it dramatically more convenient by engineering antibodies that stay in the body eight to ten times longer than the current market leader. The half-life advantage is real and confirmed in Phase 1. Whether it translates into comparable efficacy at week sixteen — the only question that matters — will be answered within the next several weeks, when EVERLAST-A data arrives. Interesting, but not actionable at the current price until that data lands.

---

The dermatology biologics market has produced one of the cleanest commercial stories in modern pharmaceuticals. AbbVie's Skyrizi — risankizumab, an IL-23 inhibitor approved in 2019 — generated $11.7 billion in 2024 and is tracking toward $20 billion annually by 2027, which would make it the largest pharmaceutical product in the world by revenue. That singular trajectory tells you almost everything you need to know about psoriasis as a therapeutic market: the mechanism works, payers cover it, dermatologists prescribe it enthusiastically, and patients renew. What it does not tell you is whether there is room for a new entrant — or what that entrant would have to offer to justify the cost and risk of a decade-long development program to get there.

The global psoriasis biologics market reached $14.3 billion in 2024 and is growing at roughly 10.5% annually toward a projected $31 billion by 2032. The patient population is stable and large: approximately 7.5 million adults in the United States carry a psoriasis diagnosis, with roughly 1.5 to 2 million in the moderate-to-severe category that qualifies for biologic therapy. These patients require lifelong treatment. The market does not churn the way a course-of-therapy drug market does — once a patient is controlled on a biologic, they tend to stay on it for years unless side effects or loss of efficacy intervenes. New entrants must therefore either displace stable patients with a meaningfully superior product or capture the flow of newly diagnosed and biologic-naive patients entering the market each year. The structural advantage of incumbency in this disease is real: switching a stable Skyrizi patient requires a compelling clinical reason, and in psoriasis, superior efficacy at equivalent dosing frequency is the only argument that consistently moves physicians.

The mechanism landscape is settled and highly competitive. IL-23 inhibitors — which block the p19 subunit of interleukin-23, disrupting the inflammatory cascade that drives plaque formation — are now the dominant class. Skyrizi holds approximately 45% of U.S. biologic psoriasis prescriptions. IL-17 inhibitors remain significant: Novartis's Cosentyx generated $4.98 billion in 2024 and Eli Lilly's Taltz is a multi-billion dollar franchise. UCB's bimekizumab, the first approved dual IL-17A/IL-17F inhibitor, entered the market in 2023 with a differentiated mechanism — blocking both IL-17A and IL-17F simultaneously — but conventional dosing at every eight weeks. The efficacy war among these agents has been largely fought to a draw at the top of the scale: Skyrizi achieves approximately 80% complete skin clearance at week twenty-eight. Bimekizumab matches or slightly exceeds that. In a market where the standard of care clears skin in four out of five patients, the clinical bar for a new entrant is exceptionally high, and competing on efficacy alone against a drug generating $11.7 billion annually is not a winning strategy for a company without the manufacturing scale, sales infrastructure, and market access apparatus of AbbVie.

Oruka Therapeutics, incorporated in February 2024 and publicly listed via merger with ARCA biopharma in September 2024, is not attempting to win on efficacy. It is attempting to win on duration. The company's two lead programs — ORKA-001, targeting IL-23p19, and ORKA-002, targeting IL-17A and IL-17F simultaneously — use antibodies engineered for dramatically extended half-lives. ORKA-001 has a confirmed half-life of approximately 100 days. Skyrizi's half-life is 10 to 13 days. ORKA-002's confirmed half-life is 75 to 80 days versus approximately 10 days for bimekizumab. If patients can achieve complete skin clearance with two injections per year instead of four or six, or potentially one injection per year instead of four, the value proposition is obvious: fewer injections, better adherence, and potentially superior durability after dosing stops. The company was assembled around this single idea, its antibodies licensed from Paragon Therapeutics — the same platform that spawned Apogee Therapeutics (targeting IL-13 for atopic dermatitis) and Spyre Therapeutics (targeting alpha4beta7 and TL1A for IBD).

The moat question requires precision. What Oruka holds is not a proprietary platform. Paragon's antibody engineering is deployed simultaneously across multiple spinouts, and Oruka holds only an exclusive worldwide license for ORKA-001 outside of IBD indications. The underlying half-life extension technology is Paragon's, not Oruka's. What Oruka has specifically is first-mover advantage in applying half-life extension to the psoriasis IL-23 and IL-17 pathways, and the quantitative case for that advantage is straightforward — the dosing interval differential is large enough to be commercially transformational rather than merely clinically notable:

Drug	Target	Half-Life	Maintenance Dosing	Injections / Year
ORKA-001 (Oruka)	IL-23p19	~100 days	Potentially annual	1–2 (target)
Skyrizi (AbbVie)	IL-23p19	10–13 days	Every 12 weeks	4
Tremfya (J&J)	IL-23p19	7–8 days	Every 8–16 weeks	3–6
ORKA-002 (Oruka)	IL-17A/F	~75–80 days	Potentially twice-yearly	2 (target)
Bimzelx (UCB)	IL-17A/F	~10 days	Every 8 weeks	6–7
Cosentyx (Novartis)	IL-17A	~27 days	Every 4 weeks	13

The table makes the half-life advantage concrete. A patient maintained on Skyrizi receives four injections per year; a patient maintained on ORKA-001, if the annual dosing hypothesis holds, receives one. That reduction in treatment burden matters not because patients find injections intolerable but because adherence to chronic biologic therapy declines with every additional injection required, and because a drug a patient takes once per year is structurally resistant to competitive switching in a way that a drug taken every twelve weeks is not. If a dermatologist switches a patient's quarterly Skyrizi to annual ORKA-001 and the patient remains clear for twelve months without an injection, the argument for switching back to quarterly dosing becomes difficult to make. That is the nature of the competitive moat Oruka is attempting to construct — not scientific exclusivity, which it does not have, but clinical stickiness, which follows from proven duration. The caveat is the same one that appears throughout this analysis: none of this has been tested in psoriasis patients yet. No major pharmaceutical company has launched an extended-half-life version of risankizumab or bimekizumab, which means the window for first approval in this approach may be several years wide — but that window exists only if Phase 2 confirms the efficacy hypothesis.

The most honest statement of where the thesis stands today: Oruka has confirmed the pharmacokinetic half of its argument and has not yet confirmed the pharmacodynamic half. Phase 1 data announced in September 2025 showed a 100-day half-life for ORKA-001 in healthy volunteers, a favorable safety profile, and sustained STAT3 pathway inhibition — a downstream marker of IL-23 blockade — through week twenty-four. Phase 1 data for ORKA-002 announced in January 2026 showed a 75-to-80-day half-life and pharmacokinetics consistent with twice-yearly dosing. These results establish that the drug stays in the body as designed and suppresses the relevant signaling pathway as expected. They do not establish that suppressing that pathway at these concentration levels, in this patient population, for this duration, produces skin clearance rates comparable to the drugs that currently dominate the market. A 100-day half-life antibody that achieves 60% PASI 100 is a clinical curiosity, not a commercial product. A 100-day half-life antibody that achieves 80% PASI 100 and demonstrates off-treatment remission is a category-creating franchise. The distance between those two outcomes is one Phase 2a trial.

The financial profile is entirely conventional for a pre-revenue clinical-stage company: no revenue, substantial and growing R&D expenditure, and a cash position built to carry the company through its first pivotal data readouts. Oruka raised approximately $475 million in concurrent private placements at the time of its September 2024 merger, financed by a consortium including Fairmount, Venrock Healthcare Capital Partners, RTW Investments, Perceptive Advisors, Blackstone Multi-Asset Investing, Avidity Partners, and Redmile Group. R&D expenses totaled $75.1 million in the partial year 2024 (February 6 through December 31) and $100.6 million in full-year 2025. The net loss in 2025 was $105.4 million. Cash and marketable securities stood at $479.6 million at December 31, 2025 — essentially unchanged from the original raise because the company successfully executed an additional financing during 2025 at higher prices as clinical execution was demonstrated on schedule. Debt is negligible at approximately $2.3 million. There is no gross margin to analyze, no operating leverage to evaluate, and no path to profitability that does not run through Phase 2 success, Phase 3 completion, and a multi-year commercial launch that cannot begin before 2030 at the earliest.

At the current quarterly R&D burn rate of approximately $27 to $29 million, Oruka has roughly fourteen to sixteen quarters of runway from its December 2025 cash position, supporting operations through 2029 without additional financing. Management has guided that the balance sheet funds multiple Phase 2 readouts: EVERLAST-A in Q2 2026, EVERLAST-B and ORCA-SURGE in 2027. The R&D trajectory below shows clinical investment accelerating as trials move from enrollment into active dosing, and shows the cash balance surprisingly intact despite two years of heavy spending — a reflection of the follow-on financing rather than capital discipline:

Quarter	R&D Expense	Operating Cash Burn	Cash Balance	Clinical Milestone
Q3 2024	$25.7M	$27.8M	~$466M	Merger closed; $475M raised
Q4 2024	$25.5M	$18.8M	$393.7M	EVERLAST-A trial design finalized
Q1 2025	$19.9M	—	—	ORKA-001 Phase 1 first dose administered
Q2 2025	$24.1M	—	—	EVERLAST-A IND clearance (July 2025)
Q3 2025	$29.0M	$21.6M	—	ORKA-001 Phase 1 data: 100-day half-life confirmed
Q4 2025	$27.6M	—	$479.6M	EVERLAST-B initiated; ORKA-002 Phase 1: 75-day half-life confirmed
Q2 2026E	~$28–30M	~$28–32M	~$445–455M	EVERLAST-A PASI 100 at week 16 — the pivotal catalyst

The table tells a story of systematic clinical advancement: every milestone hit on schedule, cash managed to extend runway through the critical first data readout, and R&D spend ramping in line with the number of active trials. What the table cannot tell you is what the Q2 2026 data will say. Enrollment for EVERLAST-A — eighty patients in a 3:1 active-to-placebo design, receiving 600 milligrams of ORKA-001 at weeks zero and four — completed in December 2025. The primary endpoint is PASI 100 at week sixteen. The EVERLAST-A design goes further: week-28 PASI 100 responders are randomized 2:1 to either no further dosing or maintenance dosing every six months, with the explicit goal of demonstrating off-treatment remission consistent with annual or semiannual dosing. That secondary data, expected in the second half of 2026, is potentially the most commercially significant result in the entire program — proof that a patient who achieves clearance can remain clear for twelve months without an additional injection.

The penetration argument runs as follows. Approximately 1.5 to 2 million Americans with moderate-to-severe psoriasis receive biologic therapy today. As of April 2026, Oruka has captured zero of them. Skyrizi has captured approximately 45% of that market and is still growing. A competing IL-23 inhibitor with dosing reduced from four injections per year to one would represent a fourfold improvement in treatment convenience with no anticipated reduction in efficacy. Even a modest five-percent market share capture over five years post-approval — in a market projected at $30 billion by the time any ORKA-001 approval could realistically occur — implies peak revenues in the range of $700 million to $1.5 billion annually. Against that potential, the Paragon licensing costs are material but not company-defining. The company has not captured any of that market. It has captured something more preliminary: confirmation that the pharmacology behaves as the engineers intended, in volunteers who did not have psoriasis.

Management is well-assembled for a company at this stage. CEO Lawrence Klein came from CRISPR Therapeutics, where he served as Chief Operating Officer through the regulatory approval of the world's first gene-edited therapy for sickle cell disease. Chief Medical Officer Joana Goncalves brings twenty years of dermatology clinical development experience, including medical affairs responsibility for Otezla at Celgene and a CMO role at Cara Therapeutics where she advanced IV KORSUVA through FDA approval. The board is populated by active executives running comparable development-stage companies: Cameron Turtle is CEO of Spyre Therapeutics, Carl Dambkowski is CMO of Apogee Therapeutics, Samarth Kulkarni is CEO of CRISPR Therapeutics, and Chris Martin, who joined the board in December 2025, was most recently Chief Commercial Officer at Verona Pharma — acquired by Merck in October 2025 for approximately $10 billion — adding rare commercial launch expertise to a board otherwise composed of development-focused executives. Klein holds approximately 927,000 shares, which is meaningful but not exceptional alignment for a CEO of a company at this valuation. The most notable insider activity over the past six months was institutional purchasing by Venrock Healthcare Capital Partners at prices around $10 to $12 per share in early 2025. No operating executive has purchased shares in the open market at current prices. Capital allocation has been appropriate: all resources directed toward advancing ORKA-001 and ORKA-002, with no acquisitions, no diversions, and no dilutive side programs.

The valuation is where the thesis becomes uncomfortable. At $60.60 per share — $0.08 below the all-time high of $60.68 reached on April 7, 2026 — Oruka carries a market capitalization of $1.56 billion. With $479.6 million in cash and marketable securities and negligible debt, the enterprise value attributable to the pipeline itself is approximately $1.08 billion. This is being paid for two programs with Phase 1 pharmacokinetic data and no efficacy data in psoriasis patients. The $1.08 billion enterprise value is entirely a probability-weighted bet on Phase 2 results and eventual approval — and the bet is placed at the all-time high, two months before the binary event that resolves the uncertainty.

The closest peer comparison is Apogee Therapeutics, the most direct analog by origin, indication, and structure. Apogee carries a market cap of $4.92 billion — more than three times Oruka's. The valuation gap reflects development stage: Apogee's lead program has reported positive Phase 2 fifty-two-week data as of March 2026 and is initiating Phase 3 in the second half of 2026. Oruka is roughly twelve months behind. If EVERLAST-A delivers efficacy results comparable to what Apogee demonstrated in atopic dermatitis, the Apogee comparator implies a re-rating toward $3 to $5 billion — a two-to-three-fold increase from the current market cap. The failure case implies a re-rating to near cash value, roughly $200 to $400 million, as the market recalibrates the probability of ORKA-002 carrying the story alone. The gap between the upside and the downside scenarios is not a reasonable risk-reward profile for a new entry at today's price.

The most credible bear argument is not about the science. The mechanism is validated — risankizumab's efficacy in IL-23p19 blockade is one of the most replicated findings in modern dermatology. The pharmacokinetics are excellent and well-characterized. The team is capable. The bear argument is about price and proximity to a binary event. Extended half-life antibodies carry a liability that is the exact inverse of their commercial advantage: when something goes wrong — an adverse event, an immunogenicity signal, an unexpected tolerability issue — the drug persists for three to four months rather than weeks. Phase 1 enrolled healthy volunteers at a single dose level in a small population and showed no severe adverse events. Phase 2 enrolls eighty psoriasis patients with potentially compromised immune responses at a 600 milligram dose over sixteen weeks of follow-up. These are not equivalent safety populations. More fundamentally, ORKA-001 is engineered to bind the same epitope as risankizumab and showed higher peak concentrations than risankizumab in Phase 1 — this is the bull case's strongest argument for efficacy parity, but pharmacokinetic superiority has not consistently predicted Phase 2 efficacy across biologic development programs, and the psoriasis disease biology involves enough patient heterogeneity that a small Phase 2a cohort can produce results that do not replicate. The bear answer to the bull case is simply: the probability is not zero, and at a price of $1.08 billion enterprise value for pre-Phase-2-efficacy-data assets, the market is already paying for a high likelihood of success. The honest response to that objection is that for a validated mechanism class with favorable Phase 1 PK data, the probability of Phase 2 efficacy parity may genuinely be high — perhaps 50% or more. But the stock has moved from $5.49 to $60.60 in the past twelve months in anticipation of that data. The premium for waiting until after the readout is not large relative to the cost of being wrong.

The investment is interesting when the price reflects the uncertainty. Before the catalyst delivers, at an all-time high that implies the market already expects a favorable result, it is not actionable. What would change this verdict: EVERLAST-A delivering PASI 100 rates at week sixteen of 75% or higher would validate the commercial thesis and reset the analytical starting point. After positive Phase 2a data, the question becomes whether off-treatment remission data through week fifty-two confirms annual dosing potential, and whether Phase 3 can be designed efficiently enough to reach approval before the large incumbents engineer competing programs. That is an investment worth evaluating at a price that reflects post-catalyst certainty rather than pre-catalyst hope. Below $30 per share, the risk-reward changes substantially — the cash alone would represent more than half the market cap, and the clinical optionality becomes available at a probability-adjusted price that compensates for the binary risk. At $60.60, the question is not whether the science is interesting. It is.

The pharmacology is sound. The team is capable. The catalyst is weeks away. The market has already priced in the answer it hopes to receive — and that is exactly the wrong moment to buy.